USC scientists create a temperature-stable vaccine for use in developing countries where refrigeration may be unavailable
USC researchers have developed a polio vaccine that doesn’t require refrigeration, meaning it could someday be used all over the world to deliver the final blow to this longtime foe.
The vaccine, which was freeze-dried into a powder, kept at room temperature for four weeks and then rehydrated, offered full protection against the polio virus when tested in mice.
Stabilization is not rocket science, so most academics don’t pay much attention to this field.
Woo-Jin Shin
“Stabilization is not rocket science, so most academics don’t pay much attention to this field,” said the study’s first author, Woo-Jin Shin, a fellow in the lab of Jae Jung, chair of the Department of Molecular Microbiology and Immunology at the Keck School of Medicine of USC. “However, no matter how wonderful a drug or vaccine is, if it isn’t stable enough to be transported, it doesn’t do anyone much good.”
The study appears in the Nov. 27 issue of the journal mBio.
Polio is on the brink of complete eradication, with just 22 reported cases worldwide in 2017. The highly infectious disease, which causes lifelong paralysis and disability mostly in young children, is a fading memory in many places. Yet in countries where vaccination rates are spotty, young children are at risk.
The biggest hitch to complete eradication has been creating a temperature-stable vaccine for use in developing countries where refrigeration may be unavailable. Recent polio cases have been reported in Nigeria, Papua New Guinea, Syria and Pakistan.
Other freeze-dried vaccines
In the United States, the polio epidemic reached its height in the 1950s. In 1957, mass immunization brought the annual number of cases down from 58,000 to 5,600. Since 1979, no cases of polio have originated in the United States.
By removing moisture through freeze-drying, researchers have created temperature-stable vaccines for measles, typhoid and meningococcal disease. But scientists haven’t been able to make a polio vaccine that retains potency through freeze-drying and rehydration.
Shin and his colleagues used two lab techniques — liquid chromatography and high-throughput screening — that allowed them to analyze a high volume of ingredients and formulations until they found one that worked.
Jung’s hope is that a foundation or company will take over the project to pay for human studies and bring the injectable vaccine onto the market.
In addition to Shin, the study’s authors are Daiki Hara and Jae Jung of the Keck School of Medicine, and Francisca Gbormittah, Hana Chang and Byeong S. Chang of Integrity Bio, a company that specializes in biologics — medicines made from substances found in living things.
Back story: During dinner three years ago, Jung and his college buddy Chang, CEO of Integrity Bio, decided to bring together Jung’s virology expertise with Chang’s expertise in stabilization. Chang paid Shin’s salary, and Jung provided supplies.
“He and I decided to do this as we are getting old and we need to directly contribute to human health and life,” Jung said. “Creative ideas always start with food and drinks.”
Learn more: Vaccine breakthrough brings researchers closer to eliminating polio worldwide
The Latest on: Temperature-stable vaccine
[google_news title=”” keyword=”temperature-stable vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Temperature-stable vaccine
- Researchers estimate vaccines have saved 154 million lives over past half-centuryon May 9, 2024 at 8:41 am
An international team of health and medical researchers including workers at the WHO, working with economists and modeling specialists, has found that the use of vaccines to prevent or treat disease ...
- AstraZeneca Withdraws Covid Vaccine as Demand Diveson May 8, 2024 at 8:20 pm
Anglo-Swedish drugmaker AstraZeneca on Wednesday said it was withdrawing Covid vaccine Vaxzevria, one of the first produced in the deadly pandemic, citing "commercial reasons" following a slump in ...
- Tailored vaccine could one day treat eczema in childrenon May 8, 2024 at 9:00 am
New research from a multi-disciplinary team at Trinity College Dublin suggests a "tailored vaccine" might hold the key to treating bacteria-driven flares of eczema in children. The work has been ...
- ‘My son’s childhood is gone – parents who don’t vaccinate their children need to hear this’on May 8, 2024 at 1:37 am
“Tom’s childhood has been destroyed, he will never get those years back. His teenage years and his adult life will be very different to the one that we’d imagined for him or he’d even imagined for ...
- Cholera is making a comeback — and the world doesn’t have enough vaccineson May 2, 2024 at 3:30 am
The global stockpile of the oral cholera vaccine — a supply whose needs are difficult ... according to experts Vox spoke with. Higher temperatures and changing weather patterns make the environmental ...
- A Better Concept For mRNA Vaccines: Self-Amplificationon April 29, 2024 at 8:38 am
Two newly reported vaccines using a self-amplifying RNA ... Some lyophilized preparations may be stable at room temperature for many months. GEMCOVAC-OM uses an anionic particle, whereas ARCT ...
- Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africaon April 25, 2024 at 12:30 am
The described vaccine platform has previously ... Stability studies have demonstrated that SuVax™ is heat stable for at least 2 years at temperatures of at least 40 degrees Celsius (104 degrees ...
- Nature Publication Highlights the Benefits of Tropis® Intradermal When Used to Administer a First-in-Class Self-Amplifying mRNA Vaccineon April 24, 2024 at 7:10 am
Nature study shows delivery of a novel self-amplifying mRNA-based vaccine with Tropis directly into the dermis significantly boosts immune responses.
- Soligenix bags orpan drug designation for Marburg virus vaccineon April 15, 2024 at 5:05 pm
The US Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient in MarVax, Soligenix’s vaccine for the prevention and post-exposure prophylaxis against ...
via Bing News